Project ECHO: Methadone in the Age of Fentanyl
August 8 – Cara Zimmerman, MD, MBA | Transition in Methadone and Buprenorphine
September 12 – David Kispert, MD | Methadone in the Age of Fentanyl
October 10 – Stephanie Nichols, PharmD, BCPP, MPH | Drug Interactions with Methadone
November 14 – Alane O’Connor DNP | Methadone and Pregnant People
December 12 – Jacquelyn Cyr, FNP | Regulations of Methadone
January 9 – Cara Zimmerman, MD, MBA | Pain and Methadone
Learning Objectives:
- Explore the role of Methadone in MOUD
- Identify where Methadone fits into the continuum of care in MOUD
- Understand the role of transitions in the employment MOUD medication
Description
Of the roughly 2.1 million U.S. adults who have opioid use disorder, 19% receive Methadone treatment. In the current illicit drug supply landscape, Methadone and other MOUD medications are a vital part of preventing overdose harm and deaths and supporting recovery. This 6-month Project ECHO will highlight Methadone as a treatment for Opioid Use Disorder, with a focus on state-of-the-art practices and treatments.
Speaker
-
David Kispert MDDave graduated from Creighton University School of Medicine in Omaha, NE in 2016. He completed his internal medicine residency at Maine Medical Center in 2019. Touched by the challenges and stigma those with substance use disorders face, he then enrolled in a one-year addiction medicine fellowship at Boston Medical Center. Upon completion in 2020, he returned to southern Maine where he continues to practice. He currently works as medical director for two opioid treatment programs in the Portland area. He lives in Portland with his loving and patient wife and two dogs, Logan and Linus.
